MITZI FLOYD: Open Payments
NPI 1356713903 · BRANDON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,672 in 88 payments from 12 companies in 2025. Trend: 2023 $1,665 · 2024 $1,475 · 2025 $1,672
Food & beverage: $1,561Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 19 | $430 |
| ABBVIE INC. | 20 | $231 |
| Janssen Pharmaceuticals, Inc | 10 | $179 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $144 |
| E.R. Squibb & Sons, L.L.C. | 6 | $136 |
| Vanda Pharmaceuticals Inc. | 4 | $107 |
| Neurocrine BioSciences, Inc. | 5 | $100 |
| Lundbeck LLC | 5 | $100 |
| Otsuka America Pharmaceutical, Inc. | 5 | $98 |
| Axsome Therapeutics, Inc. | 4 | $78 |
Products named: VRAYLAR, AUSTEDO XR, INVEGA SUSTENNA, CAPLYTA, COBENFY, UZEDY, FANAPT, INGREZZA.
Industry payments across MS — which companies pay providers there.
